

February 4, 2016



## DelMar Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016

- Presentation with live webcast on Monday, February 8th at 10:00 a.m. EST -

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 4, 2016 /PRNewswire/ - [DelMar Pharmaceuticals, Inc.](#) (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will present at the [18th Annual BIO CEO & Investor Conference](#) on Monday, February 8, 2016 at 10:00 a.m. EST in New York, NY.



Jeffrey Bacha, DelMar's Chairman and CEO, will provide an update on the ongoing clinical trial of [VAL-083](#) (*dianhydrogalactitol*) in patients with recurrent glioblastoma multiforme (GBM) as well as discuss the Company's goal to "up-list" its shares to a National U.S. Exchange.

Mr. Bacha will review [safety and efficacy data from the Phase II refractory GBM study presented at the Society for Neuro-Oncology Annual Meeting](#) and provide an update on the advancement of VAL-083 into registration-directed Phase II/III clinical trials in refractory GBM during 2016.

During his presentation, he will also review the [new Phase II clinical study with VAL-083 in patients with GBM at first recurrence/progression, prior to Avastin™ \(bevacizumab\) exposure](#), which will be conducted in collaboration with the University of Texas MD Anderson Cancer Center.

VAL-083 has demonstrated promising potential to address modern unmet medical needs in the treatment of a range of cancers, including [non-small cell lung cancer \(NSCLC\)](#), [ovarian cancers](#), [malignant pediatric brain tumors](#), and [other solid tumor types](#), especially where other therapies have failed or are predicted to give sub-optimal outcomes.

A live audio webcast of the presentation will be available by accessing DelMar's [IR Calendar](#)

in the [Investors](#) section of the Company's website ([www.DelMarPharma.com](http://www.DelMarPharma.com)). The webcast replay will be available approximately two hours after the presentation and will be accessible for one month.

### **About BIO**

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The [18<sup>th</sup> Annual BIO CEO & Investor Conference](#) is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Each year the conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. BIO also produces the [BIO International Convention](#), the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

### **About VAL-083**

VAL-083 is a "first-in-class," small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of malignant gliomas.

DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar<sup>®</sup> (temozolomide).

DelMar recently announced the completion of enrollment in a Phase II clinical trial of VAL-083 in refractory GBM. Patients have been enrolled at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO).

In the Phase I dose-escalation portion of the study, VAL-083 was well tolerated at doses up to 40mg/m<sup>2</sup> using a regimen of daily x 3 every 21 days. Adverse events were typically mild to moderate; no treatment-related serious adverse events reported at doses up to 40 mg/m<sup>2</sup>. Dose limiting toxicity (DLT) defined by thrombocytopenia (low platelet counts) was observed in two of six (33%) of patients at 50 mg/m<sup>2</sup>. Generally, DLT-related symptoms resolved rapidly and spontaneously without concomitant treatment, although one patient who presented with hemorrhoids received a platelet transfusion as a precautionary measure.

Sub-group analysis of data from the Phase I dose-escalation portion of the study suggested a dose-dependent and clinically meaningful survival benefit following treatment with VAL-083 in GBM patients whose tumors had progressed following standard treatment with

temozolomide, radiotherapy, bevacizumab and a range of salvage therapies.

Patients in a low dose ( $\leq 5\text{mg}/\text{m}^2$ ) sub-group had a median survival of approximately five (5) months versus median survival of approximately nine (9) months for patients in the therapeutic dose ( $30\text{mg}/\text{m}^2$  &  $40\text{mg}/\text{m}^2$ ) sub-group following initiation of VAL-083 treatment. DelMar reported increased survival at 6, 9 and 12 months following initiation of treatment with VAL-083 in the therapeutic dose sub-group compared to the low dose sub-group.

Further details can be found at <http://www.delmarpharma.com/scientific-publications.html>.

### **About DelMar Pharmaceuticals, Inc.**

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit <http://delmarpharma.com/>; or contact DelMar Pharmaceuticals Investor Relations: [ir@delmarpharma.com](mailto:ir@delmarpharma.com) / (604) 629-5989. Connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#). Investor Relations Counsel: Amato & Partners LLC.

### **Safe Harbor Statement**

*Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.*

Logo - <https://photos.prnewswire.com/prnh/20150909/265198LOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-present-at-the-18th-annual-bio-ceo--investor-conference-on-february-8-2016-300215082.html>

SOURCE DelMar Pharmaceuticals, Inc.

